Our Scientists

Surgery scientists, a specialized group within the medical and research community, play a pivotal role in advancing surgical practices and patient outcomes through rigorous scientific inquiry and innovative methodologies. These professionals are at the forefront of developing, testing, and implementing new surgical techniques, instruments, and technologies that enhance the precision, safety, and efficacy of surgical procedures. The field of surgical science is inherently multidisciplinary, drawing upon principles from biomedical engineering, materials science, pharmacology, and physiology to address complex surgical challenges. 

This integrative approach enables surgery scientists to not only improve existing procedures but also to pioneer entirely new surgical paradigms. Recent advancements in surgical science have been driven by the advent of minimally invasive techniques, robotic surgery, and personalized medicine. These innovations have significantly reduced recovery times, minimized surgical risks, and tailored interventions to individual patient needs. Moreover, the incorporation of data analytics and artificial intelligence into surgical planning and execution has opened new avenues for precision surgery, allowing for real-time decision-making and enhanced surgical outcomes. 

As the global burden of surgical diseases continues to rise, the role of surgery scientists becomes increasingly critical. Their research endeavors are essential in addressing the disparities in surgical care across different populations and regions, ensuring that cutting-edge surgical innovations are accessible and equitable. This research writeup delves into the current landscape of surgical science, highlighting key advancements, ongoing challenges, and future directions. By exploring the contributions of surgery scientists to the broader medical field, we aim to underscore the importance of their work in improving patient care and shaping the future of surgery.

Consultant

Dedrick Chan

Asst Professor

Wang Jiongwei

Assoc Professor

Alfredo Franco-Obregon

Assoc Professor

Glenn Kunnath Bonney

Assoc Professor

Edmund Chiong

Asst Professor

Gan Shu Uin

Assoc Professor

Phan Toan Thang

Professor

Theodoros Kofidis

Assoc Professor

Vitaly Sorokin

Senior Research Fellow

Ratha Mahendran 

Assoc Professor

Shabbir Moochhala

Dr

Mervyn 
Lim Jun Rui 

Professor

Jimmy So Bok Yan

Assoc Professor

Asim Shabbir

Assoc Professor

Tan Ker Kan

Assoc Professor

Mikael Hartman 

Included under the umbrella of University Surgical Cluster, some key research areas and strengths are the generation of minimal invasive endoscopic tools and related intellectual properties. We manufacture biosensors, flow sensors, less invasive surgical retractors and scopes. We also develop methodology to make heart and vascular surgery, more efficient and safer. In the colorectal field, we strive to improve the outcome in colorectal diseases by promoting minimal invasive surgical routes, targeting benign, anorectal disease as well as colorectal cancer. Colorectal cancer, pelvic floor disorders are further priorities, moreover, we use stem cells to address gastric cancer and discover biomarkers for locally advanced gastric cancer. We use Genomic- guided chemotherapy for gastric cancer patients who are at good risks and to address diabetes mellitus and obesity, we explore new Endoluminal Device for Duodenal exclusion for better control in the treatment of Type II diabetes and obesity In Plastic, Reconstructive & Aesthetic Surgery, we pursue scaffold technologies, adult stem cells for tissue regeneration as well as the usage of bio-imaging to better understand pathology & patho-physiology e.g. in facial trauma. 

All surgical developments have to aim at reducing patient burden, pain and surgical trauma, to distribute high standards of care to wide masses of the population in the region and the world. Without research and investment in research projects, without research infrastructure and academic commitment, medicine and surgery stagnate. Progress is eliminated. However, diseases spread and change within evolving megatrends, as countries become more industrialized, lifestyle changes and people become older. New pandemics emerge. Without research and innovative surgical therapies many organs, organ systems, human lives cannot be salvaged. It is our vocation, in alignment with the most primary principles of health care, to lead the way to the future with research, teaching and innovation, and hopefully turn scientific concepts of today to useful therapies tomorrow.

Dr Ratha Mahendran

Bladder Cancer Workgroup

Our vision is to improve patient care by making treatments safer and more efficient and developing novel therapies. We aim to achieve this through rigorous scientific research. Over the last two decades, the BCW has developed a research program encompassing clinical, translational, and innovative approaches. Here are some research themes we are currently working on.    

Genetic polymorphisms as a marker of response to BCG therapy
  
Alternative treatments for non-muscle invasive bladder cancer
such as probiotics, nano-drug formulations and implantable devices Disease models of bladder cancer such asorthotopic model and aging model.

More

Dr Wang Jiong Wei

The Wang Lab

A multidisciplinary team working on translational research in cardio-metabolic diseases: to discover pathogenic mechanisms, to identify novel therapeutic targets, and to create viable nanomedicines for targeted therapy, with a focus on the heart, the liver, and the gut.

More

Our team has been working on cardio-metabolic diseases, cardiac immunology, extracellular vesicles and nanomedicine. Our laboratory is working with various established pre-clinical animal models of human disease, including myocardial infarction, ischemia reperfusion injury, pressure overload, diet-induced heart failure), atherosclerosis and non-alcoholic fatty liver disease. The newly established NANONASH research program aims to tap unto brilliant and young scientists to develop new and effective nanomedicine-based therapies for the treatment of fatty liver disease. Our group also works on new nanomaterials and drug delivery systems (carrying small molecules, nucleic acids, RNAs etc) for translational research in cardiovascular disease, fatty liver disease and gut related disease. Our nanomedicine laboratory, the Centre for NanoMedicine, provides state-of-the-art technology to enable such research and expand the applications of nanomedicine for unmet clinical needs.

Dr Alfredo

BICEPS Laboratory

Developing targeted Magnetic Mitohormesis strategies to improve human health, longevity and physical performance.

More

Dr Dedrick Chan

Cancer Initiation and Evolution Laboratory

The Cancer Initiation and Evolution Laboratory (CIEL) is focused on understanding key events which occur along the continuum of normalcy to cancer. This includes the first changes which sets a cell on the path towards eventual cancer, as well as later events which may dictate metastasis or confer onto a cancer unique oncologic phenotypes. Currently, the laboratory has a special interest in colorectal cancer.

MOre

Dr Gan Shu Uin

Phoenix Lab of Gene and Cell Therapy

Discovery of new and improved methods for treatment of diabetes and other metabolic diseases, such as Laron’s syndrome. Viral Gene Therapy using Adeno-Associated Virus (AAV) and Lentiviral (LV) vectors. Cell therapy using Mesenchymal Stem Cells (MSCs)  

More

Dr Shabbir Moochhala

Lee Foundation Programme in the Education of Microbiome

The Lee Foundation Microbiome Education Program has been dedicated to fostering awareness and understanding of the microbiome to the society and it is headed by esteemed mentors Professor Lee Chuen Neng, Associate Professor Shabbir Moochhala and Asst. Prof Jiong-Wei Wang.

more

Dr Vitaly Sorokin

Cardiovascular Single Cell Research Lab

Cellular and Molecular Mechanisms, and Genetics behind the disease exploration to allow better prevention, prognosis, prediction behind cardiovascular disease and CVD therapeutic.

More

Dr Glenn Kunnath Bonney

The Surgical Proteomics Laboratory (SCALPEL)

SCALPEL was commissioned in February 2018 in the Institute for Health Innovation and technology (iHealthtech), NUS. Using a multidisciplinary approach, our aim is to translate scientific breakthroughs into tangible improvements in patient outcomes. Using a combination of mass spectrometry imaging, proteomics and primary patient derived organiod culture, our research is targeted towards improving the efficacy, safety and precision of chemotherapy, as well as development of mass spectrometry based platforms for real-time pathological and surgical analysis with an emphasis on pancreatic ductal adenocarcinoma (PDAC) and hepatocellular carcinoma (HCC).

More

Dr T Kofidis

Professor Theo Kofidis is Head of the Department of Cardiac-, Thoracic- and Vascular Surgery, at the National University Hospital of Singapore, Senior Consultant Cardiothoracic Surgeon, an expert minimally invasive heart surgeon and avid researcher. He is a renowned Cardiac Surgeon and strongly sought-for proctor and surgical teacher around the world. One of only very few AATS members in SE Asia, he is also an Ambassador / Steering Committee of the World Society for Cardiothoracic Surgery for the same region. He is Founder and Owner of the Company Kardia Pte Ltd, aiming at the development of disruptive heart valve- and minimally invasive heart surgery technology. He is Chairman of I.R.I.S. (Initiative for Research and Innovation in Surgery), has introduced various new technologies, and launched new types of less invasive surgery. Over the last 12 years in Singapore, he has established the most complete, pioneering and advanced Minimally Invasive Heart Surgery program in the region, and set up the most advanced hemodynamic research laboratory and Cardiovascular Surgical Research Group in Singapore, with NMRC support.

More

Dr Phan Toan Thang

Wound Healing and Stem Cell Research Lab

Research and development of novel and affordable biological products for better treatment of non-healing wounds as resulted of aged related diseases

MOre

In 2004,A/Prof Phan invented a new stem cell technology exploiting a Singapore based novel source of stem cells derived from human umbilical cord lining tissue or CLSC tech. 20 years on this technology has proven to be the optimal stem cell tech for cell therapy and regenerative medicine. With the invention, A/Prof Phan's teams have gained a great deal of publications and patents as well as a Singapore based stem cell biotech CellResearch Corp (CRC), which is recognised today as one of most success stories in Singapore and the region. CRC is an employer of more than 50 high income Singapore based workers, a funding source for my research projects and a training hub for both local and overseas students of NUS, NTU, Polytechnics, ITE and high schools for research, innovation and enterprise. CRC is still growing as a significant player in stem cell tech at the global stage and contributing to Singapore development.

RESEARCH: The team stays focus on research and development of novel and affordable biological products for better treatment of non-healing wounds as resulted of aged related diseases and is collaborating with local and international scientists to exploit CLSC tech for other therapies like cancer, diabetes, CVD and neuronal degeneration. INNOVATION: My team and I are still growing our patents portfolio and Singapore based intellectual capital both internally and externally by collaborating with scientists in NUS, Duke-NUS, NTU, A Star, SingHealth. ENTERPRISE: His teams are continuing to grow our Singapore based stem cell biotech CellResearch Corp to be a leading player at the world stage and providing mentorship and advice to NUS and Singapore biotech startups like Cellivate Technologies, Agem Bio and so on.